Intra-Cellular Therapies's Earnings: A Preview
Portfolio Pulse from Benzinga Insights
Intra-Cellular Therapies (NASDAQ:ITCI) is set to release its quarterly earnings report on November 2, 2023. Analysts estimate an EPS of $-0.56. The company's past performance shows a pattern of beating EPS estimates but experiencing a drop in share price. The stock is currently trading at $49.76, down 3.35% over the last 52-week period.
November 01, 2023 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Intra-Cellular Therapies is expected to report an EPS of $-0.56. The company has a history of beating EPS estimates but experiencing a drop in share price. The stock is currently down 3.35% over the last 52-week period.
The company's history of beating EPS estimates but experiencing a drop in share price suggests that investors may be focusing more on the company's guidance than its earnings. The stock's negative return over the last 52-week period also indicates a bearish sentiment among long-term shareholders.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100